AI Summary
→ WHAT IT COVERS Peter Attia examines why prostate cancer deaths are rising despite available screening tools, presenting data showing current USPSTF guidelines are built on a fatally contaminated study, and outlining a modern detection framework using PSA velocity, PSA density, contrast-free MRI, and transperineal biopsy to catch lethal cancers early. → KEY INSIGHTS - **PSA Velocity Over Snapshots:** A single PSA reading fluctuates up to 15% day-to-day and 40% post-ejaculation, making it unreliable in isolation. Track trajectory instead: for men with baseline PSA under 4 ng/mL, a sustained rise exceeding 0.35 ng/mL per year over 18 months is the clinical red flag warranting further investigation. - **Contrast-Free MRI Viability:** The 2025 PRIME trial demonstrated that bi-parametric MRI without gadolinium contrast detected clinically significant cancer in 143 of 490 men versus 145 with full multiparametric MRI — a statistically negligible 0.4 percentage point difference. The contrast-free scan takes 15–20 minutes versus 30–40, cutting cost and expanding access substantially. - **Transperineal Biopsy Safety:** In a multicenter phase-three trial of over 1,700 patients, transperineal biopsy produced zero infections compared to a 5–7% infection rate with the standard transrectal approach. It also detects more high-grade cancers by accessing anterior and apical prostate regions the transrectal route misses. Currently only 37% of U.S. urologists perform it. - **PLCO Study Contamination:** The cornerstone trial used to justify abandoning PSA screening was effectively comparing screened men to screened men — over 90% of the supposed control arm received at least one PSA test. A 2017 reanalysis correcting for this contamination found the same dataset supports a 27–32% reduction in prostate cancer mortality from regular PSA testing. - **Finasteride PSA Correction:** Men on finasteride for one or more years must have their raw PSA value multiplied by at least 2.0 to interpret it accurately, with correction factors rising to 2.3 after two to seven years and 2.5 beyond seven years. Any upward PSA movement while on finasteride warrants immediate clinical concern, as suppression should otherwise produce a roughly 2% annual decrease. → NOTABLE MOMENT Despite declining total prostate cancer diagnoses after the 2012 guideline shift, stage-four diagnoses climbed 6% annually in the U.S. while stage-three rose 3.3% per year — confirming that reduced screening did not reduce cancer, it simply delayed detection until the disease became incurable. 💼 SPONSORS None detected 🏷️ Prostate Cancer Screening, PSA Testing, Cancer Early Detection, Finasteride Drug Interactions, Urology Guidelines